ATAI Life Sciences is going public. MindMed Inc is hitting new highs. The two events ARE connected.
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
MindMed launches its digital medical division.
Novamind Closes Oversubscribed CAD$10 Million Private Placement
Novamind has closed on double its original target (CAD$5 million). Preparing to commence trading on the CSE (symbol "NM").
Adopt A Small Business, Save Them From Extinction
What's the best "investment advice" that any of us could receive in 2020? Invest in Small Business.
Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering
Including its new financing, Mind Cure currently has in excess of CAD$5 million in cash.
Field Trip Health Ltd. and WHOOP announce partnership to measure effect of psychedelic therapies on physiology and mental health
Field Trip announces a new clinics-based research program, beginning with psychedelic therapies for military veterans.
Delic Corp Commences Trading On CSE
Delic Corp is a Delaware-based psychedelics company that has gone public via RTO.
Psychedelic Drug Therapy: Cure Your Mind, Save Your Heart?
Will psychedelic drug therapies (simultaneously) save lives as they cure mental health disorders?
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
Numinus plans a "compassionate access" clinical trial of psilocybin to treat substance abuse.
Mydecine Innovations Group Offers Management and Clinical Trials Update
Mydecine provides an update on its Phase 2A clinical trial of psilocybin-assisted psychotherapy for the treatment of PTSD.
Mind Cure Science Advisor Becomes First CSO As It Builds World-Class Team
Mind Cure's new CSO is a decorated researcher, entrepreneur and inventor.
Field Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle Program
Field Trip is entering the (already legal) Netherlands psilocybin market with a "Field Trip Health Center" in Amsterdam.
